In NSCLC, especially adenocarcinoma, personalized therapeutic approaches have led to the development of increasingly efficacious targeted inhibitors for patients with actionable alterations, including in EGFR, ALK, KRAS, BRAF, RET, ROS1, MET, and NTRK [68]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.